Healthcare Professionals

Resolute Integrity™ DES

Zotarolimus-Eluting Coronary Stent System

DES Technology for Today + Tomorrow

Coronary Stenting in Daily Practice

The Resolute Integrity™ drug-eluting coronary stent simplifies everyday challenges in your increasingly complex clinical practice.

Featuring the unique Continuous Sinusoid Technology of Integrity™ BMS, and a biocompatible polymer specifically designed for DES, Resolute Integrity DES delivers excellent acute performance and powerful clinical performance.


Product Details

A paradigm shift in stent design and manufacturing: Continuous Sinusoid Technology

Continuous Sinusoid Technology
Flexible stent platform for outstanding flexibility and conformability

Continuous Sinusoid Technology

A single strand of cobalt alloy is formed into a sinusoid, wrapped in a helical pattern, and laser fused.

Built to deliver

  • DES technology for today + tomorrow:
    • Unique Continuous Sinusoid Technology defines current performance and enables future innovations 
  • First FDA-approved DES for the treatment of CAD in patients with diabetes2
  • Powerful clinical evidence to address challenging cases:
    • More than 7600 patients studied, including a real-world patient population3 

Incorporates the BioLinx™ biocompatible polymer specifically designed for drug-eluting stents:

  • Rapid endothelial healing4
  • Minimal inflammation4
  • Low risk of stent thrombosis5
  • Controlled drug elution5

BIO-RESORT6 and TRANSFORM OCT7 showed no benefit of bioabsorbable polymer DES over durable BioLinx polymer DES.


Product Specifications

Resolute Integrity DES Product Ordering Information

1

RESOLUTE All Comers 12-month data. RESOLUTE All Comers evaluated the Resolute™ stent.

2

Resolute Integrity DES IFU.

3

Silber S. Five-year follow-up of safety and efficacy of the Resolute zotarolimus-eluting stent: Insights from the Global RESOLUTE Clinical Trial Program in approximately 8000 patients, EuroPCR 2015.

4

In porcine models. Based on test data on file at Medtronic. May not be indicative of clinical performance.

5

Yeh et al. 5-year safety and efficacy of resolute zotarolimus-eluting stent. JACC Cardiovascular Interventions. 2017;10:247–254.

6

Von Birgelen et al. Data presented at TCT 2016. 

7

Guagliumi et al. Data presented at PCR 2016. Investigator-initiated study not funded by Medtronic.

© 2018 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. ™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. For distribution in the USA only.